8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Apr 21, 2008)

Filed April 21, 2008For Securities:LLY

Summary

Eli Lilly & Company (LLY) filed an 8-K on April 21, 2008, to report its financial results for the first quarter ended March 31, 2008. The report highlights the company's performance, providing both GAAP and non-GAAP financial measures. A key aspect of this filing is the detailed explanation of significant non-GAAP adjustments used to present a clearer view of ongoing operational performance. These adjustments include items like restructuring charges, in-process R&D costs from acquisitions and in-licensing deals, asset impairments, and tax benefits from IRS audit resolutions. The company emphasizes that these non-GAAP figures are intended to help investors understand operational trends and make meaningful period-over-period comparisons, but should be considered alongside, not as a substitute for, GAAP measures. The filing also includes financial expectations for the full year 2008, presented on both GAAP and adjusted bases.

Key Highlights

  • 1Reporting of Q1 2008 financial results and full-year 2008 financial expectations.
  • 2Use of non-GAAP financial measures to provide a clearer view of ongoing operational performance.
  • 3Significant non-GAAP adjustments in Q1 2008 include a tax benefit from IRS audit resolution and charges related to the termination of the AIR Insulin program.
  • 4Non-GAAP adjustments in prior periods (2007) include restructuring charges, in-process R&D for acquisitions (ICOS, Hypnion, Ivy), and charges related to Zyprexa product liability.
  • 5Company believes non-GAAP information aids in evaluating ongoing operations and identifying trends.
  • 6Investors are advised to consider non-GAAP measures in addition to, not as a substitute for, GAAP measures.
  • 7The filing incorporates a press release dated April 21, 2008, detailing these results and expectations.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Eli Lilly & Company's financial results for the first quarter ended March 31, 2008, and to provide updated financial expectations for the full year 2008. It includes a press release detailing these results and the company's financial outlook.

The key non-GAAP adjustments highlighted for Q1 2008 include a tax benefit from the resolution of a substantial portion of an IRS audit for 2001-2004, and charges related to asset impairments, restructuring, and termination of the AIR Insulin program. For prior periods (2007), adjustments included restructuring charges, in-process R&D for acquisitions (e.g., ICOS, Hypnion), and charges related to Zyprexa product liability.

Eli Lilly & Company provides non-GAAP financial information because they believe it helps investors evaluate ongoing operations by excluding items that are highly variable, difficult to predict, and can significantly impact reported results. This adjusted view is intended to facilitate meaningful period-over-period comparisons and trend identification.

Investors should consider the non-GAAP financial information in conjunction with, but not as a substitute for or superior to, the financial measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The company uses this non-GAAP data internally for performance evaluation and resource allocation.